OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
Identifieur interne : 000C26 ( Ncbi/Merge ); précédent : 000C25; suivant : 000C27OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
Auteurs : Raffaele Bruno [Italie] ; Giuseppe Cariti ; Paola Nasta ; Amedeo Capetti ; Veronica Ravasio ; Massimo Galli ; Enzo Raise ; Giulio Palmieri ; Claudio Iannacone ; Massimo PuotiSource :
- Liver international : official journal of the International Association for the Study of the Liver ; 2015.
Descripteurs français
- Wicri :
- geographic : Italie.
English descriptors
- KwdEn :
- Coinfection (drug therapy), Drug Therapy, Combination (methods), Genotype, HIV Infections (complications), HIV Infections (drug therapy), Hepacivirus (genetics), Hepatitis C (complications), Hepatitis C (drug therapy), Hepatitis C (genetics), Humans, Interferon-alpha (therapeutic use), Italy, Odds Ratio, Polyethylene Glycols (therapeutic use), Prospective Studies, RNA, Viral (blood), Recombinant Proteins (therapeutic use), Ribavirin (therapeutic use).
- MESH :
- chemical , blood : RNA, Viral.
- chemical , therapeutic use : Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- geographic : Italy.
- complications : HIV Infections, Hepatitis C.
- drug therapy : Coinfection, HIV Infections, Hepatitis C.
- genetics : Hepacivirus, Hepatitis C.
- methods : Drug Therapy, Combination.
- Genotype, Humans, Odds Ratio, Prospective Studies.
Abstract
Hepatitis C virus (HCV) genotype 3 (G3) is common among HIV/HCV co-infected individuals and associated with moderate sustained virological response (SVR) rates with pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy, while G2 is less frequent and associated with higher SVR. To determine SVR and other response rates, identify SVR predictors and analyse differences between G2 and G3 with PEG-IFN/RBV in a large HIV/HCV G2/3 patient population.
DOI: 10.1111/liv.12641
PubMed: 25041136
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000154
- to stream PubMed, to step Curation: 000154
- to stream PubMed, to step Checkpoint: 000077
Links to Exploration step
pubmed:25041136Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.</title><author><name sortKey="Bruno, Raffaele" sort="Bruno, Raffaele" uniqKey="Bruno R" first="Raffaele" last="Bruno">Raffaele Bruno</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Cariti, Giuseppe" sort="Cariti, Giuseppe" uniqKey="Cariti G" first="Giuseppe" last="Cariti">Giuseppe Cariti</name></author><author><name sortKey="Nasta, Paola" sort="Nasta, Paola" uniqKey="Nasta P" first="Paola" last="Nasta">Paola Nasta</name></author><author><name sortKey="Capetti, Amedeo" sort="Capetti, Amedeo" uniqKey="Capetti A" first="Amedeo" last="Capetti">Amedeo Capetti</name></author><author><name sortKey="Ravasio, Veronica" sort="Ravasio, Veronica" uniqKey="Ravasio V" first="Veronica" last="Ravasio">Veronica Ravasio</name></author><author><name sortKey="Galli, Massimo" sort="Galli, Massimo" uniqKey="Galli M" first="Massimo" last="Galli">Massimo Galli</name></author><author><name sortKey="Raise, Enzo" sort="Raise, Enzo" uniqKey="Raise E" first="Enzo" last="Raise">Enzo Raise</name></author><author><name sortKey="Palmieri, Giulio" sort="Palmieri, Giulio" uniqKey="Palmieri G" first="Giulio" last="Palmieri">Giulio Palmieri</name></author><author><name sortKey="Iannacone, Claudio" sort="Iannacone, Claudio" uniqKey="Iannacone C" first="Claudio" last="Iannacone">Claudio Iannacone</name></author><author><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25041136</idno><idno type="pmid">25041136</idno><idno type="doi">10.1111/liv.12641</idno><idno type="wicri:Area/PubMed/Corpus">000154</idno><idno type="wicri:Area/PubMed/Curation">000154</idno><idno type="wicri:Area/PubMed/Checkpoint">000077</idno><idno type="wicri:Area/Ncbi/Merge">000C26</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.</title><author><name sortKey="Bruno, Raffaele" sort="Bruno, Raffaele" uniqKey="Bruno R" first="Raffaele" last="Bruno">Raffaele Bruno</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Cariti, Giuseppe" sort="Cariti, Giuseppe" uniqKey="Cariti G" first="Giuseppe" last="Cariti">Giuseppe Cariti</name></author><author><name sortKey="Nasta, Paola" sort="Nasta, Paola" uniqKey="Nasta P" first="Paola" last="Nasta">Paola Nasta</name></author><author><name sortKey="Capetti, Amedeo" sort="Capetti, Amedeo" uniqKey="Capetti A" first="Amedeo" last="Capetti">Amedeo Capetti</name></author><author><name sortKey="Ravasio, Veronica" sort="Ravasio, Veronica" uniqKey="Ravasio V" first="Veronica" last="Ravasio">Veronica Ravasio</name></author><author><name sortKey="Galli, Massimo" sort="Galli, Massimo" uniqKey="Galli M" first="Massimo" last="Galli">Massimo Galli</name></author><author><name sortKey="Raise, Enzo" sort="Raise, Enzo" uniqKey="Raise E" first="Enzo" last="Raise">Enzo Raise</name></author><author><name sortKey="Palmieri, Giulio" sort="Palmieri, Giulio" uniqKey="Palmieri G" first="Giulio" last="Palmieri">Giulio Palmieri</name></author><author><name sortKey="Iannacone, Claudio" sort="Iannacone, Claudio" uniqKey="Iannacone C" first="Claudio" last="Iannacone">Claudio Iannacone</name></author><author><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name></author></analytic><series><title level="j">Liver international : official journal of the International Association for the Study of the Liver</title><idno type="e-ISSN">1478-3231</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coinfection (drug therapy)</term><term>Drug Therapy, Combination (methods)</term><term>Genotype</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>Hepacivirus (genetics)</term><term>Hepatitis C (complications)</term><term>Hepatitis C (drug therapy)</term><term>Hepatitis C (genetics)</term><term>Humans</term><term>Interferon-alpha (therapeutic use)</term><term>Italy</term><term>Odds Ratio</term><term>Polyethylene Glycols (therapeutic use)</term><term>Prospective Studies</term><term>RNA, Viral (blood)</term><term>Recombinant Proteins (therapeutic use)</term><term>Ribavirin (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Italy</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coinfection</term><term>HIV Infections</term><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepacivirus</term><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy, Combination</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Genotype</term><term>Humans</term><term>Odds Ratio</term><term>Prospective Studies</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Italie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hepatitis C virus (HCV) genotype 3 (G3) is common among HIV/HCV co-infected individuals and associated with moderate sustained virological response (SVR) rates with pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy, while G2 is less frequent and associated with higher SVR. To determine SVR and other response rates, identify SVR predictors and analyse differences between G2 and G3 with PEG-IFN/RBV in a large HIV/HCV G2/3 patient population.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25041136</PMID><DateCreated><Year>2015</Year><Month>01</Month><Day>13</Day></DateCreated><DateCompleted><Year>2015</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1478-3231</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Liver international : official journal of the International Association for the Study of the Liver</Title><ISOAbbreviation>Liver Int.</ISOAbbreviation></Journal><ArticleTitle>OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.</ArticleTitle><Pagination><MedlinePgn>120-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/liv.12641</ELocationID><Abstract><AbstractText Label="BACKGROUND & AIMS" NlmCategory="OBJECTIVE">Hepatitis C virus (HCV) genotype 3 (G3) is common among HIV/HCV co-infected individuals and associated with moderate sustained virological response (SVR) rates with pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy, while G2 is less frequent and associated with higher SVR. To determine SVR and other response rates, identify SVR predictors and analyse differences between G2 and G3 with PEG-IFN/RBV in a large HIV/HCV G2/3 patient population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This subgroup analysis of the prospective, observational OPERA (Optimized Pegylated interferon Efficacy and anti-Retroviral Approach) study was conducted between 2005 and 2011 in Italy in PEG-IFN/RBV-naïve HIV/HCV patients. The primary efficacy endpoint was SVR rate (HCV RNA <50 IU/ml or undetectable 24 weeks after end-of-treatment).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Five hundred and fifty-six HCV G2/3 patients (G2 n = 60; G3 n = 496) were treated with PEG-IFN alfa-2a 180 μg/week or PEG-IFN alfa-2b 1.5 μg/kg, + RBV 13.6 ± 2.3 (mean ± SD) mg/kg/day for median 47 (26-54) weeks. SVR rates were 57.7%, 68.3% and 56.5% for G2/3, G2 and G3 respectively) and RVR rates were 53.2%, 57.1% and 45.8% respectively. Independent SVR predictors were undetectable baseline HIV RNA [adjusted odds ratio (AOR), 2.64; 95% CI: 1.523-4.565, P = 0.0005], age (AOR 0.95 per year; 95% CI: 0.908-0.994, P = 0.0258) and anti-HCV treatment duration (AOR 1.034 per week; 95% CI: 1.013-1.057, P = 0.0019).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Undetectable HIV RNA, longer anti-HCV treatment adherence and younger age were independent SVR predictors in treatment-naïve HIV/HCV G2/3 patients receiving PEG-IFN/RBV. Suppressing HIV RNA replication before anti-HCV therapy and increasing adherence to PEG-IFN/RBV treatment SVR rates may improve SVR.</AbstractText><CopyrightInformation>© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bruno</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cariti</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Nasta</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Capetti</LastName><ForeName>Amedeo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ravasio</LastName><ForeName>Veronica</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Galli</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Raise</LastName><ForeName>Enzo</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Palmieri</LastName><ForeName>Giulio</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Iannacone</LastName><ForeName>Claudio</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Puoti</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Liver Int</MedlineTA><NlmUniqueID>101160857</NlmUniqueID><ISSNLinking>1478-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance></Chemical><Chemical><RegistryNumber>30IQX730WE</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060085">Coinfection</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015658">HIV Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016174">Hepacivirus</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006526">Hepatitis C</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007558">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016017">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011092">Polyethylene Glycols</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012367">RNA, Viral</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012254">Ribavirin</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV infections</Keyword><Keyword MajorTopicYN="N">hepatitis C</Keyword><Keyword MajorTopicYN="N">peginterferon alfa-2a</Keyword><Keyword MajorTopicYN="N">ribavirin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2014</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25041136</ArticleId><ArticleId IdType="doi">10.1111/liv.12641</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Capetti, Amedeo" sort="Capetti, Amedeo" uniqKey="Capetti A" first="Amedeo" last="Capetti">Amedeo Capetti</name><name sortKey="Cariti, Giuseppe" sort="Cariti, Giuseppe" uniqKey="Cariti G" first="Giuseppe" last="Cariti">Giuseppe Cariti</name><name sortKey="Galli, Massimo" sort="Galli, Massimo" uniqKey="Galli M" first="Massimo" last="Galli">Massimo Galli</name><name sortKey="Iannacone, Claudio" sort="Iannacone, Claudio" uniqKey="Iannacone C" first="Claudio" last="Iannacone">Claudio Iannacone</name><name sortKey="Nasta, Paola" sort="Nasta, Paola" uniqKey="Nasta P" first="Paola" last="Nasta">Paola Nasta</name><name sortKey="Palmieri, Giulio" sort="Palmieri, Giulio" uniqKey="Palmieri G" first="Giulio" last="Palmieri">Giulio Palmieri</name><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name><name sortKey="Raise, Enzo" sort="Raise, Enzo" uniqKey="Raise E" first="Enzo" last="Raise">Enzo Raise</name><name sortKey="Ravasio, Veronica" sort="Ravasio, Veronica" uniqKey="Ravasio V" first="Veronica" last="Ravasio">Veronica Ravasio</name></noCountry><country name="Italie"><noRegion><name sortKey="Bruno, Raffaele" sort="Bruno, Raffaele" uniqKey="Bruno R" first="Raffaele" last="Bruno">Raffaele Bruno</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C26 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000C26 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25041136
|texte= OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25041136" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a OperaV1
| This area was generated with Dilib version V0.6.21. |  |